Design Therapeutics, Inc. (DSGN) Balance Sheet
DSGN balance sheet, 2025
December 31, 2025 · U.S. dollars$226.2M assets = $13.7M liabilities + $212.5M equity
Both columns are drawn to the same scale: what DSGN owns equals what it owes plus shareholders’ equity. Hover a block for its value.
DSGN financial health
Descriptive bands, not a rating. Fiscal 2025.
DSGN balance sheet trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $90,0002019 | $226.2M2025 | +268.7%/yr | |
| Total liabilities | $3.7M2019 | $13.7M2025 | +24.2%/yr | |
| Shareholders’ equity | −$3.6M2019 | $212.5M2025 | — | |
| Cash & short-term investments | $77,0002019 | $219.8M2025 | +276.6%/yr | |
| Total debt | $695,0002019 | $1.5M2025 | +14.1%/yr | |
| Net cash (debt) | −$618,0002019 | $218.3M2025 | +$218.9M | |
| Working capital | −$3.6M2019 | $210.7M2025 | +$214.4M | |
| Book value per share | −$0.132019 | $3.712025 | — | |
| Debt / equity | 0.012021 | 0.012025 | 0.00 | |
| Shares outstanding | 27.2M2019 | 57.3M2025 | +13.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
DSGN assets
DSGN liabilities and equity
DSGN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
DSGN balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $219.8M | $245.5M | $281.8M | $330.4M | $384.1M | $36.1M | $77,000 |
| Cash & equivalents | $16.9M | $22.6M | $21.2M | $26.5M | $298.6M | $2.4M | $77,000 |
| Short-term investments | $203.0M | $222.9M | $260.6M | $303.9M | $85.5M | $33.7M | $0 |
| Receivables | $1.7M | $1.3M | $1.4M | $1.1M | $110,000 | $10,000 | $0 |
| Inventory | $0 | $0 | $0 | −$1.1M | $1.3M | $107,000 | $0 |
| Other current assets | $2.3M | $1.3M | $1.4M | $4.7M | $7,000 | $25,000 | $13,000 |
| Total current assets | $223.8M | $248.0M | $284.6M | $335.1M | $385.4M | $36.2M | $90,000 |
| Property, plant & equipment (net) | $2.4M | $3.6M | $4.6M | $5.6M | $5.1M | $71,000 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $427,000 | $430,000 | $459,000 | $0 | $212,000 | $0 |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M | $36.5M | $90,000 |
| Liabilities | |||||||
| Accounts payable | $2.3M | $2.2M | $1.9M | $3.0M | $1.6M | $1.4M | $2.5M |
| Short-term debt | $890,000 | $800,000 | $716,000 | $640,000 | $489,000 | — | $695,000 |
| Deferred revenue | — | — | — | — | — | — | $201,000 |
| Total current liabilities | $13.1M | $8.5M | $9.6M | $10.8M | $5.3M | $2.3M | $3.7M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $1.5M | $2.3M | $3.0M | $3.7M | $3.6M | $0 | — |
| Other long-term liabilities | $645,000 | $1.5M | $2.3M | $3.1M | $3.1M | $45.5M | $1,000 |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M | $47.8M | $3.7M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$297.0M | −$227.2M | −$177.6M | −$110.8M | −$47.5M | −$11.9M | −$3.6M |
| Accumulated other comprehensive income | $403,000 | $475,000 | $62,000 | −$3.4M | −$244,000 | $156,000 | — |
| Total shareholders' equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M | −$11.3M | −$3.6M |
| Key figures | |||||||
| Total debt | $1.5M | $2.3M | $3.0M | $3.7M | $3.6M | — | $695,000 |
| Net cash (debt) | $218.3M | $243.1M | $278.7M | $326.7M | $380.4M | — | −$618,000 |
| Working capital | $210.7M | $239.6M | $275.0M | $324.3M | $380.2M | $33.9M | −$3.6M |
| Tangible book value | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M | −$11.3M | −$3.6M |
| Book value per share | $3.71 | $4.28 | $4.96 | $5.88 | $8.32 | −$0.42 | −$0.13 |
| Shares outstanding | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M | 27.2M | 27.2M |
| Current ratio | 17.14 | 29.31 | 29.58 | 31.10 | 72.96 | 15.55 | 0.02 |
| Quick ratio | 16.97 | 29.16 | 29.44 | 30.76 | 72.72 | 15.49 | 0.02 |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — |
| Equity / assets | 93.9% | 96.0% | 95.9% | 95.9% | 97.8% | −31.0% | −4,046.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $207.4M | $222.8M | $219.8M | $206.0M | $216.3M | $229.7M | $245.5M | $254.1M | $261.0M | $270.7M | $281.8M | $290.9M |
| Cash & equivalents | $12.9M | $12.8M | $16.9M | $15.1M | $19.7M | $13.7M | $22.6M | $30.3M | $45.7M | $29.4M | $21.2M | $27.9M |
| Short-term investments | $194.5M | $210.1M | $203.0M | $190.9M | $196.6M | $216.0M | $222.9M | $223.7M | $215.3M | $241.3M | $260.6M | $263.0M |
| Receivables | $1.8M | $1.8M | $1.7M | $1.4M | $1.3M | $1.4M | $1.3M | $1.2M | $1.4M | $1.7M | $1.4M | $1.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$1.2M |
| Other current assets | $2.8M | $2.4M | $2.3M | $1.7M | $2.2M | $2.6M | $1.3M | $2.0M | $2.4M | $1.5M | $1.4M | $3.6M |
| Total current assets | $212.0M | $227.0M | $223.8M | $209.0M | $219.8M | $233.6M | $248.0M | $257.2M | $264.8M | $273.9M | $284.6M | $294.5M |
| Property, plant & equipment (net) | $3.1M | $3.4M | $2.4M | $2.7M | $3.1M | $3.4M | $3.6M | $4.0M | $4.3M | $4.5M | $4.6M | $4.9M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $427,000 | $427,000 | $427,000 | $429,000 | $427,000 | $430,000 | $437,000 |
| Total assets | $215.1M | $230.4M | $226.2M | $211.8M | $222.9M | $237.5M | $252.1M | $261.6M | $269.6M | $278.8M | $289.6M | $299.9M |
| Liabilities | ||||||||||||
| Accounts payable | $3.1M | $2.3M | $2.3M | $1.9M | $1.0M | $3.2M | $2.2M | $1.5M | $1.3M | $1.4M | $1.9M | $2.2M |
| Short-term debt | — | $536,000 | $890,000 | $866,000 | $844,000 | $821,000 | $800,000 | $778,000 | $757,000 | $736,000 | $716,000 | $697,000 |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | — | −$697,000 |
| Total current liabilities | $11.2M | $10.2M | $13.1M | $11.2M | $8.7M | $8.2M | $8.5M | $7.4M | $6.4M | $7.1M | $9.6M | $12.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $2.7M | $2.7M | $1.5M | $1.7M | $1.9M | $2.1M | $2.3M | $2.5M | $2.7M | $2.9M | $3.0M | $3.2M |
| Other long-term liabilities | $2.0M | $2.2M | $645,000 | $877,000 | $1.1M | $1.3M | $1.5M | $1.7M | $1.9M | $2.1M | $2.3M | $2.5M |
| Total liabilities | $13.3M | $12.4M | $13.7M | $12.1M | $9.8M | $9.6M | $10.0M | $9.2M | $8.3M | $9.2M | $12.0M | $14.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 |
| Retained earnings (deficit) | −$334.8M | −$314.6M | −$297.0M | −$281.0M | −$264.0M | −$244.9M | −$227.2M | −$213.6M | −$200.5M | −$188.7M | −$177.6M | −$165.8M |
| Accumulated other comprehensive income | −$771,000 | −$268,000 | $403,000 | $358,000 | $305,000 | $450,000 | $475,000 | $914,000 | −$217,000 | −$167,000 | $62,000 | −$1.3M |
| Total shareholders' equity | $201.9M | $218.1M | $212.5M | $199.7M | $213.0M | $227.9M | $242.1M | $252.5M | $261.2M | $269.6M | $277.7M | $285.0M |
| Key figures | ||||||||||||
| Total debt | $2.0M | $2.7M | $1.5M | $1.7M | $1.9M | $2.1M | $2.3M | $2.5M | $2.7M | $2.9M | $3.0M | $3.2M |
| Net cash (debt) | $205.4M | $220.1M | $218.3M | $204.2M | $214.3M | $227.5M | $243.1M | $251.6M | $258.3M | $267.8M | $278.7M | $287.7M |
| Working capital | $200.8M | $216.9M | $210.7M | $197.9M | $211.0M | $225.4M | $239.6M | $249.8M | $258.4M | $266.8M | $275.0M | $282.2M |
| Tangible book value | $201.9M | $218.1M | $212.5M | $199.7M | $213.0M | $227.9M | $242.1M | $252.5M | $261.2M | $269.6M | $277.7M | $285.0M |
| Book value per share | $3.23 | $3.55 | $3.71 | $3.51 | $3.75 | $4.02 | $4.27 | $4.46 | $4.62 | $4.77 | $4.95 | $5.09 |
| Shares outstanding | 62.5M | 61.4M | 57.3M | 57.0M | 56.9M | 56.8M | 56.7M | 56.6M | 56.6M | 56.5M | 56.2M | 56.0M |
| Current ratio | 18.86 | 22.28 | 17.14 | 18.71 | 25.13 | 28.37 | 29.31 | 34.61 | 41.42 | 38.61 | 29.58 | 23.77 |
| Quick ratio | 18.61 | 22.05 | 16.97 | 18.56 | 24.88 | 28.06 | 29.16 | 34.35 | 41.04 | 38.39 | 29.44 | 23.58 |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Equity / assets | 93.8% | 94.6% | 93.9% | 94.3% | 95.6% | 96.0% | 96.0% | 96.5% | 96.9% | 96.7% | 95.9% | 95.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 9, 2026); data from EODHD.
DSGN financial position
At the end of fiscal 2025 (December 31, 2025), Design Therapeutics had total assets of $226.2 million (down 10.3% from a year earlier), total liabilities of $13.7 million and shareholders' equity of $212.5 million. It held $219.8 million in cash and short-term investments against $1.5 million of debt, a net cash position of $218.3 million. Its current ratio was 17.14. In the latest quarter (ended June 30, 2026) total assets were $215.1 million and equity $201.9 million.
Related: DSGN income statement, DSGN cash flow statement, DSGN key metrics. See the DSGN stock overview for the latest quote and news.
DSGN balance sheet FAQ
What are Design Therapeutics's total assets?
Design Therapeutics reported total assets of $226.2 million at the end of fiscal 2025 (December 31, 2025), compared with $252.1 million a year earlier.
How much debt does Design Therapeutics have?
Design Therapeutics had $1.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.
How much cash does Design Therapeutics have?
Design Therapeutics held $219.8 million in cash and short-term investments at the end of fiscal 2025; with $1.5 million of debt that is net cash of $218.3 million.
What is Design Therapeutics's book value?
Design Therapeutics's shareholders' equity (book value) was $212.5 million at the end of fiscal 2025, or $3.71 per share.
What is Design Therapeutics's current ratio?
Design Therapeutics had current assets of $223.8 million and current liabilities of $13.1 million, a current ratio of 17.14 (it can cover its short-term obligations).